Genomic Profiling May Redefine DCIS Risk Assessment

Genomic profiling is emerging as a tool to redefine risk assessment in ductal carcinoma in situ (DCIS), potentially guiding more personalized treatment decisions. (Exact figures not reported in source.)

• News report highlights the growing role of genomic profiling in stratifying DCIS risk beyond conventional histopathology.
• Potential to shift clinical practice by identifying patients who may safely avoid aggressive treatment, though specifics await formal study results.
• Source is a general surgery news outlet; no original study data or numerical results were provided in the snippet.

RadPigeon summaries are original and for information only. They are not clinical advice.